Quick Answer
Core Laboratories Inc. /DE/ reported Cash and Equivalents of $22.70 million for fiscal year 2025.
Core Laboratories Inc. /DE/ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $22.70M | +18.5% |
| 2024 | $19.16M | +26.7% |
| 2023 | $15.12M | -2.0% |
| 2022 | $15.43M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.63M | +19.3% | -17.8% |
| June 30, 2025 | $31.19M | +76.3% | +41.1% |
| March 31, 2025 | $22.11M | +48.2% | +15.4% |
| December 31, 2024 | $19.16M | +26.7% | -10.8% |
| September 30, 2024 | $21.47M | +29.2% | +21.4% |
| June 30, 2024 | $17.70M | -32.5% | +18.7% |
| March 31, 2024 | $14.91M | — | -1.4% |
| December 31, 2023 | $15.12M | -2.0% | -9.0% |
- Core Laboratories Inc. /DE/ showed an increase of +18.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Core Laboratories Inc. /DE/’s cash and equivalents has grown by 47.1% (from $15.43 million to $22.70 million).
- The most recent figure is from Core Laboratories Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: